Commodore Capital LP Acquires 9.9% Stake in AN2 Therapeutics, Inc.

Commodore Capital LP, along with Commodore Capital Master LP, Michael Kramarz, and Robert Egen Atkinson, has filed a Schedule 13G indicating beneficial ownership of 3,697,435 shares of AN2 Therapeutics, Inc. common stock, representing a 9.9% stake as of March 9, 2026. This ownership includes shares directly held and shares issuable upon exercise of pre-funded warrants, subject to a 9.99% beneficial ownership limitation. The firm acts as the investment manager for Commodore Master, with Kramarz and Atkinson exercising investment discretion. The filing is based on 37,011,357 shares of common stock outstanding, reflecting recent private placement activity. The filers certify that the securities were not acquired for the purpose of influencing or changing control of the issuer.